Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast|Breast Cancer
Interventions: DRUG: Pembrolizumab Injection [Keytruda]|DRUG: Olaparib Oral Tablet [Lynparza]
Sponsor: Institut fuer Frauengesundheit
Collaborators: Merck Sharp & Dohme LLC